drugset

drugset / Trial / NCT01405794

In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm

NCT01405794 ↗

Phase 1/2 Completed 12 enrolled University of Utah

Non-randomizedCrossoverDouble-blind

Summary

The investigators propose to study oral commercial silver nanoparticle products on human enzyme activity.

Timeline

Start: 2011-07
Primary completion: 2011-11
Completion: 2011-11

Publications

Munger MA, Radwanski P, Hadlock GC, Stoddard G, Shaaban A, Falconer J, Grainger DW, Deering-Rice CE. In vivo human time-exposure study of orally dosed commercial silver nanoparticles. Nanomedicine. 2014 Jan;10(1):1-9. doi: 10.1016/j.nano.2013.06.010. Epub 2013 Jun 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	32ppm Silver Particle	Other / unclassified	32 ppm	Oral

Indications

No indication recorded.